<p>随着澳大利亚市场逐渐接近假期季节，市场出现了轻微下滑，这主要归因于在主要全球指数接近历史高点时的获利了结。在这种背景下，澳大利亚的高增长科技股为寻求创新和潜在扩张的投资者提供了引人注目的机会，特别是当这些公司在波动的经济条件下展现出韧性和适应能力时。</p>
<h3>澳大利亚十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pureprofile</td>
<td>10.51%</td>
<td>37.56%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Pro Medicus</td>
<td>19.70%</td>
<td>21.17%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Kinatico</td>
<td>13.27%</td>
<td>42.29%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Clinuvel Pharmaceuticals</td>
<td>22.02%</td>
<td>23.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>BlinkLab</td>
<td>104.90%</td>
<td>101.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xero</td>
<td>18.02%</td>
<td>24.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wrkr</td>
<td>35.94%</td>
<td>53.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Artrya</td>
<td>50.54%</td>
<td>61.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ai-Media Technologies</td>
<td>16.83%</td>
<td>94.47%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>FINEOS Corporation Holdings</td>
<td>9.22%</td>
<td>57.85%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们 ASX 高增长科技和人工智能股票筛选器中的 22 只股票的完整列表。</p>
<p>在这里，我们突出了一些我们偏好的股票。</p>
<h2>FINEOS Corporation Holdings (ASX:FCL)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> FINEOS Corporation Holdings plc 开发并销售企业索赔和保单管理软件，服务于北美、亚太、中东和非洲的寿险、意外险和健康险公司以及员工福利提供商；其市值约为 10.3 亿澳元。</p>
<p><strong>运营：</strong> FINEOS 主要通过其软件和编程部门产生收入，金额为 1.359 亿欧元。该公司专注于为各个地区的保险公司和福利提供商提供专业软件解决方案。</p>
<p>FINEOS Corporation Holdings 在澳大利亚的高增长科技领域中独树一帜，年收入增长率达到 9.2%。尽管目前尚未盈利，但该公司对保险行业软件解决方案的战略关注，体现了其在三年内实现盈利的强大计划，预计年盈利增长率将达到 57.85%。最近的高管变动旨在进一步提升治理和市场战略，Michael Kelly 转任执行董事长，并引入了行业资深专业人士如 Stephen Devine 加入董事会。这一领导层的更新有望在竞争压力中激励 FINEOS 的发展轨迹，可能加速其实现正现金流和超越市场表现的进程。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 FINEOS Corporation Holdings 的动态。</li>
<li>了解 FINEOS Corporation Holdings 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 ASX:FCL 收入和支出明细</p>
<h2>PYC Therapeutics (ASX:PYC)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> PYC Therapeutics Limited 是一家药物开发公司，专注于为澳大利亚的遗传疾病开发基于 RNA 的治疗，其市值为 9.5655 亿澳元。</p>
<p><strong>运营：</strong> 该公司通过专注于新型 RNA 治疗的发现和开发来产生收入，报告收入为 2349 万澳元。</p>
<p>PYC Therapeutics 在经历了一个充满挑战的阶段，预计未来三年收入将年缩减 5.8%，但对未来盈利仍持乐观态度，预计年盈利增长为 27.6%。这与其当前的亏损状态和去年经历的股东稀释形成鲜明对比。最近的战略董事会变动，包括任命 Peter Coleman 为独立非执行主席，强调了利用其并购专业知识引导 PYC 实现预期的 22.8% 强劲股本回报的承诺。这些举措对 PYC 逆转负面趋势并在生物科技领域抓住增长机会至关重要。</p>
<ul>
<li>在这份健康报告中解锁我们对 PYC Therapeutics 股票分析的全面见解。</li>
<li>通过我们的历史报告获取 PYC Therapeutics 的过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ASX:PYC 盈利和收入增长</p>
<h2>RPMGlobal Holdings (ASX:RUL)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> RPMGlobal Holdings Limited 开发并提供矿业软件解决方案，覆盖澳大利亚、亚洲、美洲、非洲和欧洲等多个地区，市值约为 11 亿澳元。</p>
<p><strong>运营：</strong> RPMGlobal Holdings 主要通过其软件部门产生收入，金额为 7396 万澳元，而咨询部门贡献 2477 万澳元。</p>
<p>RPMGlobal Holdings 预计年收入增长 15%，盈利激增 55%，显著超过澳大利亚市场平均水平。尽管利润率从去年的 5.3% 小幅收缩至 0.01%，但该公司对矿业创新软件解决方案的战略关注可能推动未来盈利。最近的股东会议强调了与 Caterpillar 的批准计划，可能增强 RPMGlobal 的市场地位和运营范围，使其在澳大利亚科技领域成为一个值得关注的竞争者，尽管去年财务波动中出现了 220 万澳元的一次性损失。</p>
<ul>
<li>点击这里通过我们的详细分析健康报告发现 RPMGlobal Holdings 的细微差别。</li>
<li>通过访问我们的历史表现报告评估 RPMGlobal Holdings 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth"/></p>
<p>ASX:RUL 截至 2025 年 12 月的收益和收入增长</p>
<h2>下一步</h2>
<ul>
<li>点击这里深入了解 22 只 ASX 高增长科技和人工智能股票的全貌。</li>
<li>你是否已经将投资组合多样化到这些公司？利用 Simply Wall St 的投资组合功能，密切关注影响你投资的市场动态。</li>
<li>使用 Simply Wall St 应用程序提升你的投资能力，享受免费访问覆盖每个大洲的市场情报。</li>
</ul>
<h2>对其他可能性感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

<p>澳大利亚市场在全球指数创下历史新高之际，出现了轻微下跌，投资者进行获利了结。高增长的科技股为投资者提供了机会。值得注意的公司包括 FINEOS Corporation Holdings、PYC Therapeutics 和 RPMGlobal Holdings，这些公司均显示出良好的增长率和旨在提升盈利能力的战略变化。FINEOS 专注于保险软件，PYC 专注于基于 RNA 的治疗，RPMGlobal 则专注于矿业软件解决方案。尽管面临当前挑战，这些公司在未来有潜在的扩张和改善财务表现的机会</p>

<p>As the Australian market edges towards the holiday season, it is experiencing a slight dip, largely attributed to profit-taking as major global indices approach record highs. In this context, high growth tech stocks in Australia can offer intriguing opportunities for investors seeking innovation and potential expansion, particularly when these companies demonstrate resilience and adaptability amidst fluctuating economic conditions.</p>
<div class="lb-trans"><p>随着澳大利亚市场逐渐接近假期季节，市场出现了轻微下滑，这主要归因于在主要全球指数接近历史高点时的获利了结。在这种背景下，澳大利亚的高增长科技股为寻求创新和潜在扩张的投资者提供了引人注目的机会，特别是当这些公司在波动的经济条件下展现出韧性和适应能力时。</p>
</div><h3>Top 10 High Growth Tech Companies In Australia</h3>
<div class="lb-trans"><h3>澳大利亚十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pureprofile</td>
<td>10.51%</td>
<td>37.56%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Pro Medicus</td>
<td>19.70%</td>
<td>21.17%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Kinatico</td>
<td>13.27%</td>
<td>42.29%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Clinuvel Pharmaceuticals</td>
<td>22.02%</td>
<td>23.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>BlinkLab</td>
<td>104.90%</td>
<td>101.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xero</td>
<td>18.02%</td>
<td>24.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wrkr</td>
<td>35.94%</td>
<td>53.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Artrya</td>
<td>50.54%</td>
<td>61.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ai-Media Technologies</td>
<td>16.83%</td>
<td>94.47%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>FINEOS Corporation Holdings</td>
<td>9.22%</td>
<td>57.85%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pureprofile</td>
<td>10.51%</td>
<td>37.56%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Pro Medicus</td>
<td>19.70%</td>
<td>21.17%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Kinatico</td>
<td>13.27%</td>
<td>42.29%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Clinuvel Pharmaceuticals</td>
<td>22.02%</td>
<td>23.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>BlinkLab</td>
<td>104.90%</td>
<td>101.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xero</td>
<td>18.02%</td>
<td>24.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wrkr</td>
<td>35.94%</td>
<td>53.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Artrya</td>
<td>50.54%</td>
<td>61.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ai-Media Technologies</td>
<td>16.83%</td>
<td>94.47%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>FINEOS Corporation Holdings</td>
<td>9.22%</td>
<td>57.85%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 22 stocks from our ASX High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们 ASX 高增长科技和人工智能股票筛选器中的 22 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出了一些我们偏好的股票。</p>
</div><h2>FINEOS Corporation Holdings (ASX:FCL)</h2>
<div class="lb-trans"><h2>FINEOS Corporation Holdings (ASX:FCL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for life, accident, and health insurers as well as employee benefits providers across North America, the Asia Pacific, the Middle East, and Africa; it has a market capitalization of approximately A$1.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> FINEOS Corporation Holdings plc 开发并销售企业索赔和保单管理软件，服务于北美、亚太、中东和非洲的寿险、意外险和健康险公司以及员工福利提供商；其市值约为 10.3 亿澳元。</p>
</div><p><strong>Operations:</strong> FINEOS generates revenue primarily from its software and programming segment, amounting to €135.90 million. The company focuses on providing specialized software solutions for insurers and benefits providers across various regions.</p>
<div class="lb-trans"><p><strong>运营：</strong> FINEOS 主要通过其软件和编程部门产生收入，金额为 1.359 亿欧元。该公司专注于为各个地区的保险公司和福利提供商提供专业软件解决方案。</p>
</div><p>FINEOS Corporation Holdings has positioned itself distinctively in the high-growth tech sector of Australia, with a notable annual revenue growth rate of 9.2%. Despite its current unprofitability, the company's strategic focus on software solutions for the insurance industry is underscored by robust plans for profitability within three years, reflecting an impressive expected earnings growth of 57.85% annually. Recent executive changes aim to further enhance governance and market strategy, as evidenced by Michael Kelly transitioning to Executive Chairman and the introduction of seasoned industry professionals like Stephen Devine to its Board. This leadership refresh promises to invigorate FINEOS’s trajectory amidst competitive pressures, potentially accelerating its journey towards positive cash flows and above-market performance.</p>
<div class="lb-trans"><p>FINEOS Corporation Holdings 在澳大利亚的高增长科技领域中独树一帜，年收入增长率达到 9.2%。尽管目前尚未盈利，但该公司对保险行业软件解决方案的战略关注，体现了其在三年内实现盈利的强大计划，预计年盈利增长率将达到 57.85%。最近的高管变动旨在进一步提升治理和市场战略，Michael Kelly 转任执行董事长，并引入了行业资深专业人士如 Stephen Devine 加入董事会。这一领导层的更新有望在竞争压力中激励 FINEOS 的发展轨迹，可能加速其实现正现金流和超越市场表现的进程。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of FINEOS Corporation Holdings.</li>
<li>Learn about FINEOS Corporation Holdings' historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 FINEOS Corporation Holdings 的动态。</li>
<li>了解 FINEOS Corporation Holdings 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:FCL Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:FCL 收入和支出明细</p>
</div><h2>PYC Therapeutics (ASX:PYC)</h2>
<div class="lb-trans"><h2>PYC Therapeutics (ASX:PYC)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> PYC Therapeutics Limited is a drug-development company focused on creating RNA-based treatments for genetic diseases in Australia, with a market cap of A$956.55 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> PYC Therapeutics Limited 是一家药物开发公司，专注于为澳大利亚的遗传疾病开发基于 RNA 的治疗，其市值为 9.5655 亿澳元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its focus on the discovery and development of novel RNA therapeutics, with reported revenue of A$23.49 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过专注于新型 RNA 治疗的发现和开发来产生收入，报告收入为 2349 万澳元。</p>
</div><p>PYC Therapeutics, navigating through a challenging phase with expected revenue contraction of 5.8% annually over the next three years, remains optimistic about its future profitability, projecting an earnings growth of 27.6% per annum. This contrasts starkly with its current unprofitability and shareholder dilution experienced last year. Recent strategic board changes, including the appointment of Peter Coleman as Independent Non-Executive Chair, underscore a commitment to leveraging his M&amp;A expertise to steer PYC towards anticipated robust returns on equity of 22.8%. These moves are pivotal as PYC aims to reverse negative trends and capitalize on growth opportunities in the biotech sector.</p>
<div class="lb-trans"><p>PYC Therapeutics 在经历了一个充满挑战的阶段，预计未来三年收入将年缩减 5.8%，但对未来盈利仍持乐观态度，预计年盈利增长为 27.6%。这与其当前的亏损状态和去年经历的股东稀释形成鲜明对比。最近的战略董事会变动，包括任命 Peter Coleman 为独立非执行主席，强调了利用其并购专业知识引导 PYC 实现预期的 22.8% 强劲股本回报的承诺。这些举措对 PYC 逆转负面趋势并在生物科技领域抓住增长机会至关重要。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of PYC Therapeutics stock in this health report.</li>
<li>Gain insights into PYC Therapeutics' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这份健康报告中解锁我们对 PYC Therapeutics 股票分析的全面见解。</li>
<li>通过我们的历史报告获取 PYC Therapeutics 的过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth"/></p>
<p>ASX:PYC Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:PYC 盈利和收入增长</p>
</div><h2>RPMGlobal Holdings (ASX:RUL)</h2>
<div class="lb-trans"><h2>RPMGlobal Holdings (ASX:RUL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> RPMGlobal Holdings Limited develops and provides mining software solutions across various regions including Australia, Asia, the Americas, Africa, and Europe with a market capitalization of approximately A$1.10 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> RPMGlobal Holdings Limited 开发并提供矿业软件解决方案，覆盖澳大利亚、亚洲、美洲、非洲和欧洲等多个地区，市值约为 11 亿澳元。</p>
</div><p><strong>Operations:</strong> RPMGlobal Holdings generates revenue primarily through its Software segment, accounting for A$73.96 million, while the Advisory segment contributes A$24.77 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> RPMGlobal Holdings 主要通过其软件部门产生收入，金额为 7396 万澳元，而咨询部门贡献 2477 万澳元。</p>
</div><p>RPMGlobal Holdings, with a projected annual revenue growth of 15% and earnings surge of 55%, outpaces the Australian market averages significantly. Despite a minor profit margin contraction to 0.01% from last year's 5.3%, the company's strategic focus on innovative software solutions in mining could drive future profitability. A recent shareholder meeting highlighted an approval scheme with Caterpillar, potentially enhancing RPMGlobal's market position and operational scope, marking it as a noteworthy contender in Australia’s tech landscape despite some financial volatility marked by one-off losses totaling A$2.2M last fiscal year.</p>
<div class="lb-trans"><p>RPMGlobal Holdings 预计年收入增长 15%，盈利激增 55%，显著超过澳大利亚市场平均水平。尽管利润率从去年的 5.3% 小幅收缩至 0.01%，但该公司对矿业创新软件解决方案的战略关注可能推动未来盈利。最近的股东会议强调了与 Caterpillar 的批准计划，可能增强 RPMGlobal 的市场地位和运营范围，使其在澳大利亚科技领域成为一个值得关注的竞争者，尽管去年财务波动中出现了 220 万澳元的一次性损失。</p>
</div><ul>
<li>Click here to discover the nuances of RPMGlobal Holdings with our detailed analytical health report.</li>
<li>Evaluate RPMGlobal Holdings' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的详细分析健康报告发现 RPMGlobal Holdings 的细微差别。</li>
<li>通过访问我们的历史表现报告评估 RPMGlobal Holdings 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth"/></p>
<p>ASX:RUL Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>ASX:RUL 截至 2025 年 12 月的收益和收入增长</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Gain an insight into the universe of 22 ASX High Growth Tech and AI Stocks by clicking here.</li>
<li>Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 22 只 ASX 高增长科技和人工智能股票的全貌。</li>
<li>你是否已经将投资组合多样化到这些公司？利用 Simply Wall St 的投资组合功能，密切关注影响你投资的市场动态。</li>
<li>使用 Simply Wall St 应用程序提升你的投资能力，享受免费访问覆盖每个大洲的市场情报。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实你的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

探索澳大利亚高增长科技股，重点介绍三家知名企业